Johnson & Johnson Renews Commitment to Fight Neglected Tropical Diseases, Investing in Beating Intestinal Worms, Dengue and Leprosy

NEW BRUNSWICK, N.J., June 23, 2022 – Johnson & Johnson proudly joined the global community, including governments, foundations, non-profit organizations and other pharmaceutical companies, to endorse the Kigali Declaration on Neglected Tropical Diseases. Together, we are recommitting to our long-established efforts to control and eliminate neglected tropical diseases (NTDs), a set of debilitating diseases that put at risk the health of 1.7 billion people around the world, especially the most vulnerable and underserved.Working from the lab to the last-mile of health delivery, Johnson & Johnson is today committing to fight the neglect impacting three major public health challenges: intestinal worms (soil-transmitted helminths or STH), dengue and leprosy. Endorsing the Kigali Declaration, the Johnson & Johnson Family of Companies commits to:Donate up to 200 million doses annually of mebendazole, our Janssen Pharmaceutical Companies’ medicine to treat intestinal worms, through 2025; and to Advance novel R&D programs to discover new medicines needed to beat dengue and leprosy.These diseases are a cause of significant illness, disability and death, especially among children in some of the world’s poorest and most vulnerable communities. Dengue is resurging in endemic countries and expanding into new regions as a result of the climate crisis, and leprosy is one of the world’s most ancient diseases that has yet to be eliminated. For more than 15 years, Johnson...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Health & amp; Wellness Source Type: news